Chain Length Does Matter: Development of High-Potency QS-21-Based Vaccine Adjuvants

Adjuvants are crucial agents that enhance the immunogenicity of vaccines, with QS-21 being particularly noteworthy for its potent immunostimulatory properties. QS-21, a saponin-based vaccine adjuvant isolated from the bark of Quillaja saponaria, has garnered significant attention. However, its application as vaccine adjuvant is limited due to its scarcity, complex chemical synthesis, and inherent toxicity. This study aims to develop QS-21 analogues with simplified structures, enhanced immunogenicity, and reduced toxicity. Our research findings indicate that the antibody titers generated by the analogues VA05 and VA06 in conjunction with the antigen are comparable to those induced by QS-21. With their lower toxicity, VA05 and VA06 emerge as promising candidates for next-generation adjuvant development, potentially surpassing QS-21 in both efficacy and safety.